{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 105,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "agenda",
  "function": "front_matter",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/18",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.86,
        "x": 0.07,
        "y": 0.24
      },
      "kind": "list",
      "text": "IRAK4 Degrader KT-474 Ph1 HV study: SAD/MAD data\nIRAKIMiD Degrader KT-413 Update and Clinical Plans\nSTAT3 Degrader KT-333 Update and Clinical Plans\nSTAT3 Degraders in Immune-inflammation and Fibrosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "559a637e-a293-4d8c-8384-02b1601ddc9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.12,
        "x": 0.44,
        "y": 0.04
      },
      "kind": "title",
      "text": "Agenda",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62a56e88-8986-4515-8a89-40b964898b53",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "c47cc594-b9b0-481a-afb6-043061acaf9e",
      "evidence": "The slide uses a bulleted list to structure the agenda items.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "86cb8a6d-db8c-40e2-814e-5bc67b50c2e5",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The deck showcases Kymera's pipeline, clinical trials, and potential for broad activity across diseases, creating a desire for the solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "7d2f21f7-c191-4e6f-8cc3-d5255feabd13",
      "evidence": "The deck presents a series of slides explaining the problem, complication, and solution, forming a logic chain.",
      "position": 0,
      "objective": "To demonstrate the logic behind Kymera's TPD approach and its potential to expand the druggable proteome.",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}